Systematic Review Finds No Clear Link Between GLP-1 Drugs and Suicidality | Research

The takeaway

A comprehensive systematic review of GLP-1 RA studies found no consistent evidence of increased suicidality risk associated with these medications.

No consistent suicidality signal
Systematic review across six GLP-1 RAs and five databases

What the researchers found

Systematic review across multiple databases found no consistent evidence of increased suicidality associated with GLP-1 receptor agonist use.

Why it matters

With millions of patients on GLP-1 RAs and high-profile suicide reports generating fear, rigorous evidence reviews are essential for informed clinical decision-making.

How the study worked

Comprehensive systematic review searching OVID (Medline, EMBASE, AMED, PsycINFO, JBI), PubMed, and Web of Science through May 2024.

What this study cannot tell us

Systematic review is only as good as the primary studies; most studies were not primarily designed to assess suicidality; underreporting of psychiatric events is possible.

How to read the evidence

Systematic review — thorough evidence synthesis, but primary studies were often not designed to capture suicidality as an outcome.

When this study was published

Published 2026 in Obesity Reviews. Searches through May 2024.

The bigger picture

This adds to the growing body of evidence (including the FDA's own assessment) suggesting GLP-1 RAs do not increase suicide risk, helping to counter misinformation.

Questions still open

Should ongoing GLP-1 RA trials include validated psychiatric assessment tools?
Are there specific subpopulations at higher psychiatric risk during GLP-1 RA treatment?

Common questions

Do GLP-1 drugs cause suicidal thoughts?

This comprehensive review of all available evidence found no consistent link between GLP-1 medications and suicidality. While any mental health changes should be reported to a doctor, the data is reassuring.

Why were there concerns about suicide and GLP-1 drugs?

Individual case reports prompted regulatory agencies to investigate. Both the FDA and multiple research reviews have found no consistent signal, but monitoring continues as more data accumulates.

Read the original research

Association of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.

Obesity reviews : an official journal of the International Association for the Study of Obesity, e70120

View on PubMed ↗Publisher’s paper ↗

Citation

Au, Hezekiah C T; Zheng, Yang Jing; Le, Gia Han; Wong, Sabrina; Teopiz, Kayla M; Kwan, Angela T H; Rosenblat, Joshua D; Mansur, Rodrigo B; Choi, Hayun; McIntyre, Roger S. (2026). Association of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.. Obesity reviews : an official journal of the International Association for the Study of Obesity, e70120. https://doi.org/10.1111/obr.70120